FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration
Kaiku Health raises €4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi
Challenge Qualité de vie du patient 2018 : l’appel à projets est ouvert !
Debiopharm's vision of healthcare is not limited to making new medicines available. We strongly believe that you can be an actor in your own medical care. Your safety is our top priority.MORE ABOUT CLINICAL TRIALS
© 2018 Debiopharm Group™